<DOC>
	<DOC>NCT02237079</DOC>
	<brief_summary>The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. The recruitment will be performed at Tulane Health Sciences Center.</brief_summary>
	<brief_title>Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)</brief_title>
	<detailed_description />
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal women (&lt;5y since final menstrual period) with age between 5060y Symptomatic (hot flashes, vaginal dryness) or asymptomatic BMI 2645 kg/m2 (Overweight, Obesity I and Obesity II) Fasting glucose &lt;125mg/dl Triglycerides &lt;200mg/dl Normal mammogram within past 12 months Physician clearance Amenorrhea from other causes (Hyperandrogenemia and anovulation) type 2 and type 1 diabetes Medications: diabetes or diabetic drugs, dyslipidemia, estrogen/progestin therapy, antidepressants and antipsychotics, antiretroviral (HIV), oral steroids, weight loss drugs â‰¤ 3 month washout of birth control pill (often prescribed for postmenopausal symptoms) Hysterectomy (partial or complete) Contraindications to estrogen treatment (unusual vaginal bleeding, blot clots, hepatic disease, bleeding disorder, past/present history of breast or uterine cancer, pregnant, breastfeeding)</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>